Factors Predicting the Adherence to the Therapy of Italian IBD Patients

Table 3

Oral 5-ASA compliance (high/moderate versus low) according to different confounders.

	N	OR (95% CI)	aOR (95% CI)
Gender
Males	72	1	1
Females	56	0.76 (0.37–1.56)	0.77 (0.35–1.71)
Age groups
<30 years	48	1	1
31–50 years	46	2.41 (1.04-5.54)	1.79 (0.69–4.60)
>50 years	34	7.45 (2.46–22.56)	5.18 (1.47–18.2)
Type of disease
CD	50	1	1
UC	78	1.37 (0.66–2.84)	1.64 (0.70–3.83)
Disease activity
Remission	77	1	1
Active	51	1.35 (0.64–2.82)	1.62 (0.70–3.74)
Time from diagnosis
<1 year	15	1	1
1–5 years	55	2.25 (0.70–7.21)	2.20 (0.61–7.95)
>5 years	58	3.61 (1.11–11.74)	2.64 (0.71–9.81)
Concomitant drugs
No	91	1	1
Yes	37	3.51 (1.40–8.82)	2.06 (0.73–5.83)

Adjusted for sex, age groups, type of disease, disease activity, time from diagnosis, and concomitant drugs when nonstratified for. CD = Crohn’s disease; UC = ulcerative colitis.